We know MRD sensitivity is
personal
What would it mean for your clinical trials if you could detect tumor burden at ultra-low levels?
We’ve reimagined what’s possible from an MRD assay. With its unique design, NeXT Personal® delivers both ultra-sensitivity and specificity to empower successful clinical trials. This innovative assay is designed to detect MRD months earlier (GenTraceID technology) while allowing you to track responses to therapy and reliably identify clinically relevant variants throughout a patient’s journey (VariNTrack technology).
Read about how we achieve specificity without compromising sensitivity:
The NeXT Personal Assay
Optimize your clinical trials and increase their chance of success with our ultra-sensitive tumor-informed liquid biopsy.
Reliable Ultra Sensitivity
Confidently detect low tumor burden down to 1 part per million.
Unmatched Insights
Track patient-specific tumor mutations & understand mechanisms of resistance.
Broad Inputs and Applications
Get comprehensive results from challenging samples.
GenTraceID
This patented technology delivers ultra-high sensitivity and specificity to power our genome-wide tumor-informed assay
-
10x–100x more sensitive than other methods
-
Advanced error and noise
suppression
VariNTrack
This patented technology enables you to simultaneously track variants with a single assay to see the full picture of cancer evolution.
-
Track and annotate driver and resistance mutations
-
Decipher clonal evolution and escape mechanisms